A respected pharmaceutical industry professional, Loretta M. Itri MD, FACP currently serves as Chief Medical Officer at Aadi Bioscience, Inc where she has oversight responsibility for the development of Fyarro (nab sirolimus), a novel mTOR inhibitor approved by the FDA for the treatment of malignant PEComa, and under registration directed development in a tumor agnostic study of patients with truncating TSC1-2 alterations. Immediately prior to her current position, she was Chief Medical Officer at Immunomedics, Inc. where she had oversight responsibility for the successful accelerated FDA approval of TRODELVY (sacituzumab govitecan) for the treatment of TNBC and metastatic urothelial cancer . In both recent positions, she is responsible for all R&D activities, including Clinical Pharmacology, Regulatory Affairs, Clinical Trials Phases 1-4, Clinical Operations, Drug Safety and Medical Affairs. Immunomedics was subsequently acquired by Gilead. Prior to this appointment, Dr. Itri was Executive Vice President for Global Health Sciences and Regulatory at The Medicines Company where she was involved in the development of multiple agents, including Inclisiran. The Medicines Company was subsequently acquired by Novartis. Prior to joining MDCO, Loretta Itri was President of Pharmaceutical Development at Genta, Inc. where she played a vital role in the development of therapeutic agents for CLL and breast cancer. Earlier in her career Dr. Itri was Senior Vice President of Medical Affairs at Ortho Biotech, and J&J's Pharmaceutical Research Institute where she led clinical and regulatory activities across all therapeutic areas and oversaw the development of a diverse group of therapeutic agents including Tramadol, Topiramate, Procrit, Levofloxin and Leustatin. She began her pharmaceutical career at Hoffman-LaRoche where she was Assistant Vice President for Oncology and Immunology/Virology and worked extensively on the development of interferons and retinoids.Dr. Itri received her BS degree magna cum laude from Long Island University and her MD degree from New York Medical College. She undertook residency training at the State University of New York-Stony Brook and an oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC) where she was an adjunct attending physician for more than 15 years. Dr. Itri has twice served as a member of the NCI's Board of Scientific Counselors and has published and lectured extensively on oncology drug development.